Improving CAR T-Cell Persistence

Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in hematological settings, patients that respond to CAR T therapies remain at risk of relapsing due to several facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrobon, Violena, Todd, Lauren Anne, Goswami, Anghsumala, Stefanson, Ofir, Yang, Zhifen, Marincola, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509430/
https://www.ncbi.nlm.nih.gov/pubmed/34639168
http://dx.doi.org/10.3390/ijms221910828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509430/
https://www.ncbi.nlm.nih.gov/pubmed/34639168
http://dx.doi.org/10.3390/ijms221910828

Ejemplares similares